NANETS' will annonce it's featured keynote speaker in 2019.

In 2018 we were pleased to have John Minna, MD, UT Southwestern. 

The Molecular Pathogenesis of Neuroendocrine Lung Cancers With Translation to the Clinic

Neuroendocrine lung cancers include small cell lung cancer (SCLC), non-small cell lung cancers with neuroendocrine phenotypes, and pulmonary carcinoids. There has been great strides and the molecular characterization of all of these types including genome-wide mutation, copy number variation, mRNA and proteomics expression, and epigenomic analyses on large numbers of tumors. There has been development of a large array of preclinical models of these neuroendocrine tumors including tumor cell lines, xenografts, patient and circulating tumor cell-derived xenografts (PDXs, CDXs), and genetically engineered mouse models (GEMMs). Together these have provided an unprecedented detailed view of the molecular pathogenesis of neuroendocrine lung cancers, including the diversity of their cells of origin, and also models for developing new therapeutic approaches including personalization of treatment for individual patients. Important themes that have and are developing include: the important role of TP53 and RB1 mutations; deregulated expression of Myc family members and lineage oncogenes (ASCL1, NEUROD1, POU2F3) and the super-enhancers they identify; Notch signaling; replication stress; and the inter and intra-tumor heterogeneity found with these detailed molecular analyses. The challenge now is to use all of these data and preclinical models followed by clinical translational trials, to integrate these new findings with currently available chemotherapy, radiation therapy, immunotherapy approaches to identify additional therapeutic approaches coupled with precision medicine biomarkers to personalized therapy for individual patients leading to long-term disease-free survival. In addition, we need to develop this information into new ways for the early detection and prevention of neuroendocrine lung malignancies.

 

More about Dr. Minna:

2018 Keynote John Minna

Dr. Minna is Director of the Hamon Center for Therapeutic Oncology Research, and Professor of Internal Medicine and Pharmacology at The University of Texas Southwestern Medical Center. He holds the Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology and the Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research (1991-present). He graduated from Stanford Medical School where he did research with Dr. Leonard Herzenberg, was a resident at Massachusetts General Hospital, a Research Associate at the National Heart Lung and Blood Institute (under Dr. Marshal Nirenberg), Chief of the Section of Somatic Cell Genetics, Chief of the NCI-VA and then NCI-Navy Medical Oncology Branches at the National Cancer Institute (1975-1991). His work has focused on understanding the molecular pathogenesis of lung cancer and translating this into the clinic. As part of this he has trained many investigators in lung cancer research. He has leads a joint Lung Cancer NCI Special Program of Research Excellence (SPORE) grant between UTSW and the MD Anderson Cancer Center, and is part of several NCI and State of Texas Cancer Prevention and Research Institute (CPRIT) multi-investigator grants to discover new therapeutic approaches and personalized medicine for lung cancer. He co-leads the Experimental Therapeutics Program for the UTSW Simmons Cancer Center. He has received numerous awards and has served on the Scientific Advisory Boards for several Cancer Centers as well as for the National Cancer Institute, and the Board of Directors for American Association for Cancer Research and American Society of Clinical Oncology.